Topiramate plus ASMs vs placebo plus ASMs: Number of participants with ≥ 75% reduction in all seizures
Topiramate plus ASMs showed no clear difference in number of participants with ≥ 75% reduction in all seizures compared with placebo plus ASMs (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Topiramate plus ASMs vs placebo plus ASMs Number of participants with ≥ 75% reduction in all seizures · Lennox‐Gastaut syndrome, any age Topiramate plus ASMs showed no clear difference in number of participants with ≥ 75% reduction in all seizures compared with placebo plus ASMs (low certainty). Anti‐seizure medications for Lennox‐Gastaut syndrome (2021) · Cochrane Headline outcomes only | Peto OR 8.22 [0.6, 112.62] | 1 study · 98 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.